INHIBITION OF BASAL AND ACTH-STIMULATED CORTISOL SECRETION IN HUMANS USING AN ORAL, NONPEPTIDE ACTH ANTAGONIST (CRN04894)

Alan Krasner, Christine Ferrara-Cook, Rosa Luo, Stephanie Miller, Ajay Madan, Yang Wang, Martha Hernandez-Illas, Peter J. Trainer, R. Scott Struthers, Stephen F. Betz
Disclosures

Crinetics Pharmaceuticals, Inc. is the sponsor and source of funding for the study of its investigational compound, CRN04894

• All other authors listed, except M. Hernandez-Illas and A. Madan, are employees of Crinetics

• A. Madan was an employee and is currently a consultant for Crinetics
There Are No ACTH Receptor Blocking Agents Available to Treat ACTH Driven Diseases

All currently approved therapies and agents in development act upstream or downstream of ACTH

- Pituitary Directed Agents to Suppress ACTH Secretion
  - Available: glucocorticoids, pasireotide, cabergoline
    - Limited efficacy
    - Safety issues
  - In Development: CRF antagonists

- Adrenal Steroidogenesis Inhibitors
  - Available: ketoconazole/levoketoconazole, metyrapone/osilodrostat
    - Limited Efficacy
    - Safety Issues
    - Low Adherence

- Glucocorticoid Receptor Antagonist
  - Available: mifepristone
    - Efficacy difficult to assess
    - Safety issues
  - In Development: relacorilant

CRN04894: Preclinical Evidence for ACTH Antagonism

CRN04894 is a potent ($K_b = 0.4$ nM) competitive antagonist of ACTH signaling

**Mechanism of action**
- Designed to compete with ACTH for a common binding site in order to block the ACTH-induced signaling
- Relative affinity and concentration of CRN04894 and ACTH potentially determine balance of occupancy (competitive antagonism)

**Acute suppression of ACTH-induced corticosterone observed in rats**

**Experiment designed to mimic disease:**
- CRN04894 orally administered
- Administer IV bolus of ACTH after 60 minutes
- Marked suppression of ACTH with increasing doses of CRN04894
- Analogous ACTH challenge in Phase 1 POC
Phase 1, Randomized, Double Blind, Placebo-controlled SAD/MAD Trial in Healthy Volunteers

**Design**

**Single ascending dose (250 mcg ACTH stim)**

- SAD1 (10 mg @0800)
- SAD2 (20 mg @0800)
- SAD3 (40 mg @0800)
- SAD4 (80 mg @0800)

**Additional PD Cohorts (1 mcg ACTH stim)**

- SAD5 (80 mg @0800)

**Multiple ascending dose (1 mcg ACTH stim)**

- MAD1 (40 mg @0800)
- MAD2 (40 mg @2200)
- MAD3 (60 mg @2200)
- MAD4 (80 mg @2200)
- MAD5 (40 mg BID @0800 & 2200)

**Objectives**

**Safety & tolerability**

**Pharmacokinetics**

- After first dose and at steady state
- Daily pre- and post-dose

**Pharmacodynamics**

- Serum cortisol, 24 hr. UFC, ACTH, A4, aldosterone
  - 24h circadian sampling: Baseline and multiple occasions post-dose
  - ACTH stimulation tests performed in SAD and MAD
Safety Summary—Combined SAD and MAD

No serious adverse events. All adverse events considered mild/moderate

Treatment emergent adverse events in ≥2 ‘4894 treated subjects

<table>
<thead>
<tr>
<th>Most Frequent TEAEs*</th>
<th>Placebo (SAD+MAD) (N=25) n (%)</th>
<th>‘4894 (SAD+MAD) (N=63) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucocorticoid deficiency</td>
<td>1 (4.0%)</td>
<td>11 (17.5%)</td>
</tr>
<tr>
<td>Headache</td>
<td>5 (20.0%)</td>
<td>6 (9.5%)</td>
</tr>
<tr>
<td>Dermatitis contact</td>
<td>0</td>
<td>5 (7.9%)</td>
</tr>
<tr>
<td>COVID-19</td>
<td>1 (4.0%)</td>
<td>3 (4.8%)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>1 (4.0%)</td>
<td>3 (4.8%)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>1 (4.0%)</td>
<td>2 (3.2%)</td>
</tr>
<tr>
<td>Erythema</td>
<td>0</td>
<td>2 (3.2%)</td>
</tr>
<tr>
<td>Palpitations</td>
<td>1 (4.0%)</td>
<td>2 (3.2%)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>0</td>
<td>2 (3.2%)</td>
</tr>
</tbody>
</table>

AE: Adverse event; TEAE: Treatment emergent adverse event; SAD: Single-ascending dose; MAD: Multiple-ascending dose; ECG: Electrocardiogram.

- As expected, glucocorticoid deficiency, defined as 08:00 cortisol level <5 mcg/dL, was the most common treatment related adverse event and seen only in MAD cohorts (8 during dosing, 4 after completion of dosing)
  - These subjects experienced no symptoms suggestive of clinical adrenal insufficiency
  - Physiologic replacement glucocorticoid was co-administered with continued study drug per protocol
- No study drug discontinuations due to treatment related AEs
- 4 subjects with new COVID-19 infections were sent home after 4 days of dosing during the MAD.
  - Make up subjects were subsequently enrolled and evaluated for the full 10 days of dosing
- No safety signals seen with vital signs, laboratory testing, ECGs
Pharmacokinetics of Night-Time (10 pm/2200) Dosing Cohorts in the MAD Portion of the Study

MAD PK consistent with expectations from SAD data at the same doses

**Steady State PK**

- Oral bioavailability
- Half-life of ~24 hours
- Rapidly absorbed with a $t_{\text{max}}$ of ~1-2 hours
- Dose proportional exposure
- PK profile is consistent with morning, nighttime, or BID dosing

**Concentration-Time Profile at Steady State (Day 10)**

Data shown are mean ± SEM. N=1 subject was an outlier and excluded in 60 mg cohort; MAD: Multiple-ascending dose; SAD: Single-ascending dose; PK: Pharmacokinetics; BID: Twice daily.
Dose-Dependent Suppression of Serum Cortisol Below Normal Levels

Day 9 Cortisol Profiles

Change in Cortisol from Baseline

Data shown are mean ± SEM. White asterisks in graph on upper right represent values for subjects who received glucocorticoid rescue; since GC add-back last administered at 14:00 it is expected to not contribute to 08:00 plasma levels. PBO: Placebo; HV: Healthy volunteers.
CRN04894 Potently Suppressed Adrenal Activity as Measured by Urinary Free Cortisol

Data shown are median ± IQR. Includes data from subjects receiving GC rescue.
Loss of Cortisol Negative Feedback Resulted in HV ACTH Comparable to That Seen in Disease States

Data shown are mean ± SEM using Luminex assay which reports values ~3.9-fold lower than more commonly used clinical Roche assay. All subjects receiving GC add back (in addition to ‘4894) are pooled across cohorts and depicted as a separate group; 1. Raff et al. Compr Physiol 2015, 2. Petersen Acta Pediatr Scand 1981, 3. NBIX ENDO Online 2020 presentation; HV: Healthy volunteer PBO: Placebo; GC: glucocorticoid.
CRN04894 Maintained Cortisol Below Normal Levels After ACTH Challenge Test on Top of Sustained Elevated ACTH

Data shown are mean ± SEM; one subject in 80 mg MAD arm did not receive ACTH challenge.
Suppression of Basal and ACTH Stimulated Androstenedione and Aldosterone

Androstenedione (A4)

Aldosterone

Data shown are mean ± SEM. One subject in 80 mg MAD arm did not receive an ACTH challenge at end of study.
Conclusions

• Safety:
  • CRN04894 was well tolerated in healthy volunteers

• Pharmacokinetic profile:
  • Rapidly absorbed after oral administration ($t_{\text{max}} \sim 1$-2 hrs)
  • Dose proportional increases in exposure from 10 to 80 mg
  • Half-life of $\sim 24$ hours, expected to be suitable for once daily dosing

• Pharmacodynamics:
  • Dose-dependent suppression of adrenal function (serum cortisol, 24 hr. UFC, androstenedione, and aldosterone) in healthy volunteers

• Phase 2 trials currently under development to evaluate CRN04894 in patients with classic Congenital Adrenal Hyperplasia and ACTH dependent Cushing’s syndrome
Thank you to the clinical trial volunteers and the drug discovery and development professionals who made this study possible